News Headlines Article

Drug maker scratches employees, shakes up C-suite after psoriasis drug troubles
San Francisco Business Times

Drug developer XenoPort Inc. lost its CEO, will lay off about 25 employees and will seek a partner for a questionable mid-stage treatment for the the patchy skin disease known as psoriasis. The layoffs were practically footnoted in a press release Thursday in which the Santa Clara company (NASDAQ: XNPT) announced the immediate retirement of founder and CEO Ronald Barrett and a new strategy that focuses on its restless legs syndrome treatment Horizant.